Last reviewed · How we verify
NCT06728527: PartBreCon
PARTial BREast RECONstruction With Chest Wall Perforator Flap
trial in Breast Cancer Early Stage Breast Cancer (Stage 1-3) in 1,001 participants. Currently enrolling.
31 May 2026
Quick facts
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,001 |
| Start date | 1 June 2023 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Breast Cancer Early Stage Breast Cancer (Stage 1-3) — all drugs for Breast Cancer Early Stage Breast Cancer (Stage 1-3) →
- Breast Carcinoma — all drugs for Breast Carcinoma →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Breast Surgery — all drugs for Breast Surgery →
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Who can join
18 and older, female only, with Breast Cancer Early Stage Breast Cancer (Stage 1-3) or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to ascertain the outcomes following partial breast reconstruction using chest wall perforator flaps after breast conservation surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06728527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Currently open trials in the same condition.
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT06781996 — A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva · Phase 3 · recruiting
- NCT06970912 — ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · recruiting
- NCT07206394 — Feasibility Trial of ScarWork for Post-breast Surgery Pain Syndrome. · NA · recruiting
- NCT06995118 — The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast · NA · recruiting
Other Cambridge University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
- NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
- NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
- NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06728527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06728527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing